Home/Supreme Court/Mylan Pharms. v. Acorda Therapeutics

Mylan Pharms. v. Acorda Therapeutics

137 S. Ct. 625, 196 L. Ed. 2d 580, 85 U.S.L.W. 3327, 2017 U.S. LEXIS 603
CourtSupreme Court of the United States
DecidedJanuary 9, 2017
DocketNo. 16–360.
StatusPublished

This text of 137 S. Ct. 625 (Mylan Pharms. v. Acorda Therapeutics) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mylan Pharms. v. Acorda Therapeutics, 137 S. Ct. 625, 196 L. Ed. 2d 580, 85 U.S.L.W. 3327, 2017 U.S. LEXIS 603 (U.S. 2017).

Opinion

Justice ALITO took no part in the consideration or decision of this petition.

Free access — add to your briefcase to read the full text and ask questions with AI

Cite This Page — Counsel Stack

Bluebook (online)
137 S. Ct. 625, 196 L. Ed. 2d 580, 85 U.S.L.W. 3327, 2017 U.S. LEXIS 603, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mylan-pharms-v-acorda-therapeutics-scotus-2017.